trending Market Intelligence /marketintelligence/en/news-insights/trending/5-iWAj5IXsgaxjKgCunm7A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ViiV seeks US FDA approval to offer HIV drug Dovato as 'switch' treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ViiV seeks US FDA approval to offer HIV drug Dovato as 'switch' treatment

ViiV Healthcare Ltd. is seeking U.S. approval to expand the use of its two-drug HIV treatment Dovato to patients who are already on a three-drug regimen.

If approved, Dovato will be available as a "switch treatment" for adults with HIV-1 who are already seeing benefits from an existing treatment regimen, usually a three-drug combo containing tenofovir, alafenamide and fumarate. ViiV's Dovato is only available in the US for HIV patients who have never received treatment for their disease.

It is also approved in Europe for patients with no known or suspected resistance to lamivudine, one of two medicines that make up Dovato, which also contains dolutegravir.

ViiV is majority owned by GlaxoSmithKline PLC and also counts Pfizer Inc. and Shionogi & Co. Ltd. as its shareholders.

The company's filing is based on data from a phase 3 trial called Tango, which showed Dovato worked as well as a three-drug treatment regimen in patients who switched to ViiV's medicine. In July, the London-based company announced results from two post-approval studies that reached the same conclusion in patients who had not previously been treated.

"Today's submission takes us a step closer toward offering this option for virologically suppressed adults living with HIV who are looking to treat HIV with fewer drugs," Kimberly Smith, head of research and development at ViiV Healthcare, said in a statement.

Approximately 1.1 million people in the U.S. are affected by HIV, of which 15% do not know they have the infection, according to a U.S. Food and Drug Administration estimate.